Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Inc. Borsa (RARE) Ultime notizie

Ultragenyx given Ritter Center Corporate Impact Award - North Bay Business Journal

North Bay Business Journal

Ultragenyx given Ritter Center Corporate Impact Award - North Bay Business Journal

North Bay Business Journal

Nanoscope Therapeutics Appoints SVP of Regulatory and Quality - dallasinnovates.com

dallasinnovates.com

Nanoscope Therapeutics Appoints SVP of Regulatory and Quality - dallasinnovates.com

dallasinnovates.com

MSN - MSN

MSN

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Amalgamated Bank Purchases 1427 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Defense World

M&T Bank Corp Takes $310000 Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Defense World

Ultragenyx maintains Outperform rating amid ION582 data release By Investing.com - Investing.com Canada

Investing.com Canada

Ultragenyx maintains Outperform rating amid ION582 data release - Investing.com Australia

Investing.com Australia

Ultragenyx maintains Outperform rating amid ION582 data release - Investing.com

Investing.com

Swiss National Bank Lowers Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Defense World

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates - Yahoo Lifestyle Australia

Yahoo Lifestyle Australia

Mucopolysaccharidosis Type I Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, by ... - openPR

openPR

Van ECK Associates Corp Increases Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Defense World

Learn to Evaluate (RARE) using the Charts - Stock Traders Daily

Stock Traders Daily

Ultragenyx: 1Q Earnings Snapshot - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Ultragenyx reports serious adverse effects in gene therapy trial - MSN

MSN

Ultragenyx Pharmaceutical (RARE) Stock Forecast and Price Target 2024 - MarketBeat

MarketBeat

At Ultragenyx Emil Kakkis is getting creative in the fight against ultrarare disease - San Francisco Business Times - The Business Journals

The Business Journals

RARE December 2025 Options Begin Trading - Nasdaq

Nasdaq

At Ultragenyx Emil Kakkis is getting creative in the fight against ultrarare disease - The Business Journals

The Business Journals

Ultragenyx to Participate at Bank of America's 2024 - GlobeNewswire

GlobeNewswire

Ultragenyx to Participate at Bank of America's 2024 Healthcare Conference - Yahoo Finance

Yahoo Finance

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World

Defense World

Russell Investments Group Ltd. Acquires 16728 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Defense World

Ultragenyx Pharmaceutical's (RARE) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World

Defense World

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $109.00 by Analysts at Canaccord Genuity Group - MarketBeat

MarketBeat

Ultragenyx: 2Q Earnings Snapshot - Yahoo Canada Shine On

Yahoo Canada Shine On

Ultragenyx executive sells shares worth over $15,000 By Investing.com - Investing.com Australia

Investing.com Australia

Ultragenyx executive sells shares worth over $15,000 By Investing.com - Investing.com Australia

Investing.com Australia

Ultragenyx executive sells shares worth over $15,000 By Investing.com - Investing.com UK

Investing.com UK

Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y

Zacks Investment Research

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $47.00 - MarketBeat

MarketBeat

Earnings call: Ultragenyx Q1 2024 results show strong clinical progress - Investing.com

Investing.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $47.00 - MarketBeat

MarketBeat

Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance

Yahoo Finance

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates - Zacks Investment Research

Zacks Investment Research

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewswire

GlobeNewswire

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire Inc.

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update - GlobeNewswire

GlobeNewswire

Repligen (RGEN) Misses Q1 Earnings Estimates

Zacks Investment Research

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

GlobeNewswire Inc.

Allspring Global Investments Holdings LLC Buys 548 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World

Defense World

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143 ... - Yahoo Finance

Yahoo Finance

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

GlobeNewswire Inc.

Ultragenyx Earns Award for Outstanding Contributions to the Massachusetts Economy - The Bedford Citizen

The Bedford Citizen